Zolgensma, the one-off gene replacement therapy for treating spinal muscular atrophy from Novartis subsidiary AveXis that has been at the center of a row over a controversial lottery-style managed access program, may be just a few months away from being approved in the EU.
Critical Juncture In Zolgensma EU Market Quest
Expensive And Controversial Gene Therapy Reaches CHMP
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
